This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT00153010 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 430 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Alzheimer Disease |
| Interventions | NS 2330 (Tesofensine) |
| Start | Feb 2003 |
| Primary completion | Mar 2005 |
| Study completion | Not stated |
| Results posted | Not yet |
| Registry last updated | Oct 29, 2013 |
Compounds on this site that cite this trial
What the registry says the trial is about
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Changes in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) | week 0, 4, 9, 14 and 20 |
13 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
